MX2021015302A - Metodos de purificacion de anticuerpos y composiciones de estos. - Google Patents
Metodos de purificacion de anticuerpos y composiciones de estos.Info
- Publication number
- MX2021015302A MX2021015302A MX2021015302A MX2021015302A MX2021015302A MX 2021015302 A MX2021015302 A MX 2021015302A MX 2021015302 A MX2021015302 A MX 2021015302A MX 2021015302 A MX2021015302 A MX 2021015302A MX 2021015302 A MX2021015302 A MX 2021015302A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- purification
- antibodies
- vedolizumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859580P | 2019-06-10 | 2019-06-10 | |
| PCT/US2020/037069 WO2020252072A1 (en) | 2019-06-10 | 2020-06-10 | Antibody purification methods and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015302A true MX2021015302A (es) | 2022-01-18 |
Family
ID=73782230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015302A MX2021015302A (es) | 2019-06-10 | 2020-06-10 | Metodos de purificacion de anticuerpos y composiciones de estos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220259291A1 (https=) |
| EP (1) | EP3980119A4 (https=) |
| JP (2) | JP7753105B2 (https=) |
| CN (4) | CN114025843B (https=) |
| AR (1) | AR119268A1 (https=) |
| AU (1) | AU2020290999A1 (https=) |
| BR (1) | BR112021024848A2 (https=) |
| CA (1) | CA3143169A1 (https=) |
| IL (1) | IL288830A (https=) |
| MA (1) | MA56132A (https=) |
| MX (1) | MX2021015302A (https=) |
| PL (1) | PL439807A1 (https=) |
| TW (1) | TW202112800A (https=) |
| WO (1) | WO2020252072A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| EP4380948A4 (en) * | 2021-08-05 | 2025-07-16 | Dr Reddys Laboratories Ltd | METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY |
| WO2023031965A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | Method to obtain a purified antibody composition |
| WO2023180523A1 (en) * | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| WO2006026759A2 (en) * | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| JP6592426B2 (ja) * | 2013-03-15 | 2019-10-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製 |
| PL3116891T3 (pl) * | 2014-03-10 | 2020-07-27 | Richter Gedeon Nyrt. | Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania |
| WO2018104893A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
-
2020
- 2020-06-10 EP EP20823674.5A patent/EP3980119A4/en active Pending
- 2020-06-10 AR ARP200101639A patent/AR119268A1/es unknown
- 2020-06-10 CA CA3143169A patent/CA3143169A1/en active Pending
- 2020-06-10 JP JP2021573301A patent/JP7753105B2/ja active Active
- 2020-06-10 CN CN202080042562.6A patent/CN114025843B/zh active Active
- 2020-06-10 CN CN202411105034.7A patent/CN118909120A/zh active Pending
- 2020-06-10 WO PCT/US2020/037069 patent/WO2020252072A1/en not_active Ceased
- 2020-06-10 CN CN202411109409.7A patent/CN118909121A/zh active Pending
- 2020-06-10 PL PL439807A patent/PL439807A1/pl unknown
- 2020-06-10 BR BR112021024848A patent/BR112021024848A2/pt unknown
- 2020-06-10 TW TW109119565A patent/TW202112800A/zh unknown
- 2020-06-10 AU AU2020290999A patent/AU2020290999A1/en active Pending
- 2020-06-10 MA MA056132A patent/MA56132A/fr unknown
- 2020-06-10 US US17/596,422 patent/US20220259291A1/en active Pending
- 2020-06-10 CN CN202411104704.3A patent/CN118909119A/zh active Pending
- 2020-06-10 MX MX2021015302A patent/MX2021015302A/es unknown
-
2021
- 2021-12-09 IL IL288830A patent/IL288830A/en unknown
-
2025
- 2025-02-14 JP JP2025022330A patent/JP2025087720A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118909121A (zh) | 2024-11-08 |
| JP2022536659A (ja) | 2022-08-18 |
| AU2020290999A1 (en) | 2022-02-03 |
| CN118909120A (zh) | 2024-11-08 |
| CN118909119A (zh) | 2024-11-08 |
| CN114025843B (zh) | 2026-01-09 |
| AR119268A1 (es) | 2021-12-09 |
| CN114025843A (zh) | 2022-02-08 |
| JP7753105B2 (ja) | 2025-10-14 |
| EP3980119A4 (en) | 2023-06-07 |
| WO2020252072A1 (en) | 2020-12-17 |
| US20220259291A1 (en) | 2022-08-18 |
| PL439807A1 (pl) | 2022-12-05 |
| TW202112800A (zh) | 2021-04-01 |
| IL288830A (en) | 2022-02-01 |
| JP2025087720A (ja) | 2025-06-10 |
| EP3980119A1 (en) | 2022-04-13 |
| BR112021024848A2 (pt) | 2022-01-18 |
| CA3143169A1 (en) | 2020-12-17 |
| MA56132A (fr) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015302A (es) | Metodos de purificacion de anticuerpos y composiciones de estos. | |
| JOP20230312A1 (ar) | أجسام مضادة لـ ccr8 واستخداماتها | |
| PL439808A1 (pl) | Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał | |
| EA201992670A1 (ru) | Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител | |
| EA201592192A1 (ru) | Способ очистки моноклональных антител | |
| EA201100668A1 (ru) | Способы продуцирования антител из плазматических клеток | |
| EA202092884A1 (ru) | Композиции с высокой концентрацией антител | |
| IL310186B1 (en) | Plasma kallikrein binding proteins | |
| EA201171018A1 (ru) | Биореактор для культивирования клеток млекопитающих | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| RU2013152816A (ru) | АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА | |
| EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
| SA523451582B1 (ar) | Ccr8 الأجسام المضادة لـ | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| AR119270A1 (es) | MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7 | |
| JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| TR201914501A2 (tr) | Aeroponi̇k i̇ç ortam bi̇tki̇ yeti̇şti̇rme modülleri̇ | |
| SA523450167B1 (ar) | أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها | |
| PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
| EA201270701A1 (ru) | Ингибирующие металлопротеины антитела | |
| ZA202305072B (en) | Cd1a antibodies and uses thereof | |
| EP4364755A4 (en) | COMPOSITION CONTAINING A MONOCLONAL ANTIBODY TO SUPPRESS CLOSTRIDIUM DIFFICILE BACTERIA | |
| EA202192893A1 (ru) | Среда для культивирования эукариотических клеток | |
| JOP20200106A1 (ar) | جسم مضاد أحادي النسيلة مضاد لـ il-5r? |